Shore Capital reiterated their hold rating on shares of AstraZeneca (LON:AZN) in a research note released on Monday morning.

Several other analysts have also recently weighed in on AZN. JPMorgan Chase & Co. set a GBX 5,800 ($75.55) price target on shares of AstraZeneca and gave the company a buy rating in a research note on Monday, May 28th. Liberum Capital reissued a hold rating on shares of AstraZeneca in a research note on Wednesday, May 30th. Goldman Sachs Group set a GBX 3,750 ($48.85) price target on shares of AstraZeneca and gave the company a sell rating in a research note on Wednesday, May 30th. Deutsche Bank reissued a buy rating on shares of AstraZeneca in a research note on Wednesday, June 6th. Finally, Citigroup reissued a buy rating on shares of AstraZeneca in a research note on Friday, June 8th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of Hold and an average price target of GBX 5,689.45 ($74.11).

AstraZeneca stock opened at GBX 5,669 ($73.84) on Monday. AstraZeneca has a 1-year low of GBX 4,260 ($55.49) and a 1-year high of GBX 5,520 ($71.90).

The business also recently disclosed a dividend, which was paid on Monday, September 10th. Investors of record on Thursday, August 9th were given a dividend of GBX 68.40 ($0.89) per share. The ex-dividend date was Thursday, August 9th. This represents a dividend yield of 1.19%.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: NASDAQ

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.